Cargando…

CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients

OBJECTIVE: To assess if the percentage of CD3(+)CD4(+)CD62L(+) cells in cryopreserved peripheral blood mononuclear cells (PBMCs) (here termed %CD62L) can predict risk of developing progressive multifocal leukoencephalopathy (PML) and better inform the physician for benefit–risk assessment of nataliz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lieberman, Linda A., Zeng, Wanyong, Singh, Carol, Wang, Wenting, Otipoby, Kevin L., Loh, Christine, Plavina, Tatiana, Gorelik, Leonid, Ransohoff, Richard M., Cahir-McFarland, Ellen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776091/ https://www.ncbi.nlm.nih.gov/pubmed/26718566 http://dx.doi.org/10.1212/WNL.0000000000002314

Ejemplares similares

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
por: Antoniol, Caroline, et al.
Publicado: (2015)

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
por: Dong-Si, Tuan, et al.
Publicado: (2014)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome
por: Maillart, Elisabeth, et al.
Publicado: (2017)

Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients
por: Reid, Carl E., et al.
Publicado: (2011)

Treatment of natalizumab‐associated PML with filgrastim
por: Stefoski, Dusan, et al.
Publicado: (2019)

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
por: Ryerson, Lana Zhovtis, et al.
Publicado: (2019)

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
por: Toboso, Inmaculada, et al.
Publicado: (2020)

Improving risk‐stratification of natalizumab‐associated PML
por: Tugemann, Bastian, et al.
Publicado: (2021)

A link between long-term natalizumab dosing in MS and PML: Putting the puzzle together
por: Major, Eugene O., et al.
Publicado: (2016)

7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study
por: Sinnecker, Tim, et al.
Publicado: (2015)

Concomitant granule cell neuronopathy in patients with natalizumab-associated PML
por: Wijburg, Martijn T., et al.
Publicado: (2016)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment
por: Himedan, Mai, et al.
Publicado: (2017)

Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities
por: Honce, Justin M., et al.
Publicado: (2015)

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
por: Plavina, Tatiana, et al.
Publicado: (2017)

Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus
por: Werner, Milton H., et al.
Publicado: (2016)

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
por: Malucchi, Simona, et al.
Publicado: (2016)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Maraviroc in PML-IRIS: A separate ball game under HIV infection and natalizumab?
por: Steiner, Israel, et al.
Publicado: (2017)

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study
por: Santiago-Setien, Pilar, et al.
Publicado: (2023)

Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS): “a case report from Ireland with review of literature, clinical pitfalls and future direction”
por: Mansoor, Salman, et al.
Publicado: (2021)

Adaptive Mutations in the JC Virus Protein Capsid Are Associated with Progressive Multifocal Leukoencephalopathy (PML)
por: Sunyaev, Shamil R., et al.
Publicado: (2009)

Metabolic profiles by (1)H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML)
por: Schneider, Ruth, et al.
Publicado: (2017)

Latent Membrane Protein 1 Is Dispensable for Epstein-Barr Virus Replication in Human Embryonic Kidney 293 cells
por: Geiser, Vicki, et al.
Publicado: (2011)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development
por: Meira, Maria, et al.
Publicado: (2016)

Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML
por: Alleg, Manel, et al.
Publicado: (2020)

Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment
por: Muñoz-Vendrell, Albert, et al.
Publicado: (2023)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab
por: Berkovich, Regina, et al.
Publicado: (2021)

Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
por: Plavina, Tatiana, et al.
Publicado: (2014)

Natalizumab treatment reduces L-selectin (CD62L) in CD4(+) T cells
por: Spadaro, Michela, et al.
Publicado: (2015)

JC Polyomavirus Abundance and Distribution in Progressive Multifocal Leukoencephalopathy (PML) Brain Tissue Implicates Myelin Sheath in Intracerebral Dissemination of Infection
por: Wharton, Keith A., et al.
Publicado: (2016)

Disease activity following pregnancy-related discontinuation of natalizumab in MS
por: Kleerekooper, Iris, et al.
Publicado: (2017)

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS
por: Gahlen, Anna, et al.
Publicado: (2017)

Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS
por: Largey, Fabienne, et al.
Publicado: (2019)

A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes
por: Clifford, David B., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_69rsrhi2sa33ge3kecd4ncjjll